Sector
PharmaceuticalsOpen
₹13.6Prev. Close
₹13.6Turnover(Lac.)
₹0.03Day's High
₹13.6Day's Low
₹13.552 Week's High
₹27.5152 Week's Low
₹10.56Book Value
₹-13.55Face Value
₹10Mkt Cap (₹ Cr.)
13.5P/E
0EPS
0Divi. Yield
022 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
18 Nov 2023
12:00 AM
AGM
Announcement Date: 18 Nov, 2023
29 Dec 2023
12:00 AM
EGM
21 Nov 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -22.37 | -20.62 | -17.36 | -12.39 |
Net Worth | -12.44 | -10.69 | -7.43 | -2.46 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 12.25 | 7.84 | 13.57 | 20.45 |
yoy growth (%) | 56.19 | -42.2 | -33.65 | 8.48 |
Raw materials | -8.74 | -4.52 | -6.84 | -10.4 |
As % of sales | 71.34 | 57.67 | 50.4 | 50.84 |
Employee costs | -3.1 | -3.22 | -4.93 | -5.3 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -3.99 | -3.68 | -3.18 | -1.18 |
Depreciation | -0.66 | -0.72 | -0.7 | -0.64 |
Tax paid | -0.96 | 0.83 | 0.67 | 0.41 |
Working capital | -5.79 | 5.62 | -2.44 | -2.57 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 56.19 | -42.2 | -33.65 | 8.48 |
Op profit growth | -19.05 | 12.27 | 2,443.81 | -109.04 |
EBIT growth | -15.71 | 12.46 | 327.74 | -209.11 |
Net profit growth | 74.64 | 13.08 | 227.43 | -2,127.21 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Vimal D Shah
Independent Director
Hiten Parikh
Independent Director
S A M Azmathullah
Independent Director
Susmita Mahapatra
Company Sec. & Compli. Officer
Prerna Karwa
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Norris Medicines Ltd
Summary
Norris Medicines Ltd was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments. The Company was subsequently converted into Public Limited Company on 7th March 1992. The unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The Company got into the business in the year 1990. Commercial production of the formulation unit commenced in Nov.91. The project commence in March 1992. Thereafter, the Company came out with a Public Issue aggregating Rs 5 cr in Dec.93 to expand its existing capacity for tablets, capsules, etc, besides diversifying into bulk drugs and setting up an injectables unit. The project costing Rs 14.21 Crore was financed through loans and equity, which got completed in 1995.In 2006, the Company launched Diabetic & Cardiac products; launched Dental product in 2007; launched New Molecule Tolperisone with Paracetamol tablet in 2012; in 2013, it extended Anti malarial range with Artemether Lumefantrine tablet & dry syrup. During the year 2013-14, the Company undertook the upgradation of Sterile Injectable Plant. The Company is one of the leading Indian manufacturers of Injections and Medicinal formulations. The Company is engaged into Health Care Industry and has 2 plants situated at GIDC, Ankleshwar, Gujarat. Both plants of the Company are WHO cGMP approved. At present, it has renovated the Sterile Injectable Plant, which is as per
Read More
What is the Norris Medicines Ltd share price today?
The Norris Medicines Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹13.5 today.
What is the Market Cap of Norris Medicines Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Norris Medicines Ltd is ₹13.50 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Norris Medicines Ltd?
The PE and PB ratios of Norris Medicines Ltd is 0 and -1.00 as of 22 Jul ‘24
What is the 52 Week High and Low of Norris Medicines Ltd?
The 52-week high/low is the highest and lowest price at which a Norris Medicines Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Norris Medicines Ltd is ₹10.56 and ₹27.51 as of 22 Jul ‘24
What is the CAGR of Norris Medicines Ltd?
Norris Medicines Ltd's CAGR for 5 Years at 7.13%, 3 Years at 19.60%, 1 Year at 8.80%, 6 Month at -30.15%, 3 Month at -0.80% and 1 Month at 17.55%.
What is the shareholding pattern of Norris Medicines Ltd?
The shareholding pattern of Norris Medicines Ltd is as follows:
Promoters - 34.01 %
Institutions - 0.07 %
Public - 65.92 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
